Lene Uhrbom – Molecular and functional investigations of primary malignant glioma
Our research is focused on different diagnoses of primary malignant glioma for which there is an acute need of new therapies. These brain tumours can occur at any age but are most frequent in older adults. We work with patient-derived glioma models and validated mouse models to uncover biology and regulation with the goal to identify vulnerabilities to which new therapies can be directed.
Primary malignant glioma comprises a large group of diagnoses that can affect both children and adults. Our studies are focused on diffuse gliomas, and in particular the adult tumours glioblastoma IDH wild-type, astrocytoma IDH-mutant and the childhood tumour diffuse pediatric-type high-grade glioma.
Common to these diagnoses is that in spite of extensive treatment with surgery, radiation therapy and chemotherapy there will be treatment-resistant cancer cells remaining in the large majority of patients, which will cause a lethal relapse most often in close proximity to the resection cavity.
Our projects build on two decades of studies, data and publications in the field of brain tumour biology. We work with patient tissues, patient-derived cell cultures and validated mouse models, and use a wide range of functional, phenotypic and molecular analyses to answer questions related to cancer origin, development and therapy resistance.
Biobank with tissues and cell cultures from patients
To increase the likelihood of our results being clinically applicable we are careful to perform our research in models that are biologically relevant and reflect the vast heterogeneity of malignant glioma. To make that possible we have in collaboration with other research groups at the department established a functional biobank, HGCC (Human Glioblastoma Cell Culture), which consists of patient samples and cell cultures from hundreds of patients, of which most are glioblastoma IDH wild-type and the samples taken from the bulk tumour.
My research group is now continuing this work to extend the biobank with more patient samples and cell cultures, focusing on IDH-mutant tumours and samples from the diffusely invasive outer tumour edge.
Projects
- Cancer cell diversity in IDH-mutant grade 4 astrocytoma
- Function and signaling of LGR5 in glioblastoma
- Molecular delineation of diffuse pediatric-type high-grade glioma development from a defined glial cell of origin
- Biology and targets of the relapse-causing diffusely invasive glioblastoma cells at the outer tumor edge
- Mechanisms dictating survival in epigenetic glioblastoma subgroups
Group members
Publications
TAK1 inhibition leads to RIPK1-dependent apoptosis in immune-activated cancers
Part of Cell Death and Disease, 2024
Part of Molecular Oncology, p. 238-260, 2023
Live Detection of Neural Progenitors and Glioblastoma Cells by an Oligothiophene Derivative
Part of ACS Applied Bio Materials, p. 3790-3797, 2023
Novel cancer gene discovery using a forward genetic screen in RCAS-PDGFB-driven gliomas
Part of Neuro-Oncology, p. 97-107, 2023
Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma
Part of Cancer Cell, p. 1134-1151, 2023
Wnt signaling regulates MFSD2A-dependent drug delivery through endothelial transcytosis in glioma
Part of Neuro-Oncology, p. 1073-1084, 2023
Part of Nature Communications, 2022
- DOI for Cell-lineage controlled epigenetic regulation in glioblastoma stem cells determines functionally distinct subgroups and predicts patient survival
- Download full text (pdf) of Cell-lineage controlled epigenetic regulation in glioblastoma stem cells determines functionally distinct subgroups and predicts patient survival
Part of Nucleic Acids Research, 2021
Part of JCI Insight, 2021
Part of Glia, p. 1228-1240, 2020
A Patient-Derived Cell Atlas Informs Precision Targeting of Glioblastoma
Part of Cell Reports, 2020
BET and Aurora Kinase A inhibitors synergize against MYCN-positive human glioblastoma cells
Part of Cell Death and Disease, 2019
Part of Oncoimmunology, 2019
Part of Journal of Pathology, p. 228-240, 2019
Microglia Induce PDGFRB Expression in Glioma Cells to Enhance Their Migratory Capacity
Part of iScience, p. 71-83, 2018
Part of Oncogene, p. 2515-2531, 2018
Glioblastoma Cell Malignancy and Drug Sensitivity Are Affected by the Cell of Origin
Part of Cell Reports, p. 977-990, 2017
Part of Frontiers in Oncology, 2017
Part of Cancer Research, p. 1741-1752, 2017
Part of Cancer Research, p. 802-812, 2017
Part of Scientific Reports, 2016
Case-specific potentiation of glioblastoma drugs by pterostilbene
Part of Oncotarget, p. 73200-73215, 2016
Part of Cell Reports, p. 2994-3009, 2016
Part of Oncotarget, p. 80382-80390, 2016
Part of European Journal of Pharmacology, p. 101-107, 2015
Part of Oncotarget, p. 23647-23661, 2015
Part of EBioMedicine, p. 1351-1363, 2015
Part of Acta Physiologica, p. 100-100, 2014
Part of Journal of Neuroscience, p. 14644-14651, 2014
Selective Calcium Sensitivity in Immature Glioma Cancer Stem Cells
Part of PLOS ONE, 2014
Part of Cell, p. 313-328, 2014
Part of PLOS ONE, 2013
- DOI for Adenovirus Serotype 5 Vectors with Tat-PTD Modified Hexon and Serotype 35 Fiber Show Greatly Enhanced Transduction Capacity of Primary Cell Cultures
- Download full text (pdf) of Adenovirus Serotype 5 Vectors with Tat-PTD Modified Hexon and Serotype 35 Fiber Show Greatly Enhanced Transduction Capacity of Primary Cell Cultures
Part of Neuro-Oncology, p. 1469-1478, 2013
miRNA-21 is developmentally regulated in mouse brain and is co-expressed with SOX2 in glioma
Part of BMC Cancer, p. 378, 2012
Part of Upsala Journal of Medical Sciences, p. 113-121, 2012
CGGBP1 regulates cell cycle in cancer cells
Part of BMC Molecular Biology, p. 28, 2011
Forced expression of Sox21 inhibits Sox2 and induces apoptosis in human glioma cells
Part of International Journal of Cancer, p. 45-60, 2011
Part of PLOS ONE, 2011
Part of Neoplasia, p. 492-503, 2011
RAD51 can inhibit PDGFB-induced gliomagenesis and genomic instability
Part of Neuro-Oncology, p. 1277-1287, 2011
Histidine-rich glycoprotein can prevent development of mouse experimental glioblastoma
Part of PLoS ONE, 2009
IGFBP2 is a candidate biomarker for Ink4a-Arf status and a therapeutic target for high-grade gliomas
Part of Proceedings of the National Academy of Sciences of the United States of America, p. 16675-16679, 2009
Oligodendrocyte progenitor cells can act as cell of origin for experimental glioma
Part of Oncogene, p. 2266-2275, 2009
Part of Oncogene, p. 1537-1548, 2009
Loss of Arf causes tumor progression of PDGFB-induced oligodendroglioma
Part of Oncogene, p. 6289-6296, 2007
Part of Molecular Cancer Research, p. 891-897, 2007
Cell type-specific tumor suppression by Ink4a and Arf in Kras-induced mouse gliomagenesis.
Part of Cancer Res, p. 2065-9, 2005
Part of Nat Med, p. 1257-60, 2004
Identification of candidate cancer-causing genes in mouse brain tumors by retroviral tagging
Part of Proceedings of the National Academy of Sciences of the United States of America, p. 11334-11337, 2004
Part of Cancer Research, p. 4305, 2003
Part of Development, Genes and Evolution, p. 476-487, 2003
Part of Cancer Res, p. 5551, 2002
Modeling gliomagenesis with somatic cell gene transfer using retroviral vectors.
Part of J Neurooncol, p. 297-305, 2001
Part of Int J Cancer, p. 398-406, 2000
Induction of brain tumors in mice using a recombinant PDGF B retrovirus
Part of Cancer Research, p. 5275-5279, 1998
Induction of senescence in human malignant glioma cells by p16INK4A
Part of Oncogene, p. 111, 1997